Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators.

Circulation. 2019 Jan 15;139(3):351-361. doi: 10.1161/CIRCULATIONAHA.118.038352.

PMID:
30586723
2.

Hepatic insulin extraction in NAFLD is related to insulin resistance rather than liver fat content.

Utzschneider KM, Kahn SE, Polidori DC.

J Clin Endocrinol Metab. 2018 Dec 19. doi: 10.1210/jc.2018-01808. [Epub ahead of print]

PMID:
30566676
3.

A Call for Improved Reporting of Human Islet Characteristics in Research Articles.

Poitout V, Satin LS, Kahn SE, Stoffers DA, Marchetti P, Gannon M, Verchere CB, Herold KC, Myers MG Jr, Marshall SM.

Diabetes. 2018 Dec 14. pii: dbi180055. doi: 10.2337/dbi18-0055. [Epub ahead of print] No abstract available.

PMID:
30552106
4.

A call for improved reporting of human islet characteristics in research articles.

Poitout V, Satin LS, Kahn SE, Stoffers DA, Marchetti P, Gannon M, Verchere CB, Herold KC, Myers MG Jr, Marshall SM.

Diabetologia. 2019 Feb;62(2):209-211. doi: 10.1007/s00125-018-4784-y. Epub 2018 Dec 14. No abstract available.

PMID:
30547229
5.

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators.

JAMA. 2018 Nov 9. doi: 10.1001/jama.2018.18269. [Epub ahead of print]

PMID:
30418475
6.

Genetic Ancestry Markers and Difference in A1c Between African American and White in the Diabetes Prevention Program.

Hivert MF, Christophi CA, Jablonski KA, Edelstein SL, Kahn SE, Golden SH, Dagogo-Jack S, Mather KJ, Luchsinger JA, Caballero AE, Barrett-Connor E, Knowler WC, Florez JC, Herman WH.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):328-336. doi: 10.1210/jc.2018-01416.

PMID:
30358859
7.

Higher High Density Lipoprotein 2 (HDL2) to Total HDL Cholesterol Ratio Is Associated with a Lower Risk for Incident Hypertension.

Hwang YC, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ.

Diabetes Metab J. 2018 Sep 28. doi: 10.4093/dmj.2018.0053. [Epub ahead of print]

8.

Association of Thigh Muscle Mass with Insulin Resistance and Incident Type 2 Diabetes Mellitus in Japanese Americans.

Han SJ, Boyko EJ, Kim SK, Fujimoto WY, Kahn SE, Leonetti DL.

Diabetes Metab J. 2018 Dec;42(6):488-495. doi: 10.4093/dmj.2018.0022. Epub 2018 Sep 5.

9.

Design and validation of a novel estimator of visceral adipose tissue area and comparison to existing adiposity surrogates.

Wander PL, Hayashi T, Sato KK, Uehara S, Hikita Y, Leonetti DL, Kahn SE, Fujimoto WY, Boyko EJ.

J Diabetes Complications. 2018 Nov;32(11):1062-1067. doi: 10.1016/j.jdiacomp.2018.09.004. Epub 2018 Sep 11.

PMID:
30236542
10.

Chronic kidney disease attenuates the plasma metabolome response to insulin.

Roshanravan B, Zelnick LR, Djucovic D, Gu H, Alvarez JA, Ziegler TR, Gamboa JL, Utzschneider K, Kestenbaum B, Himmelfarb J, Kahn SE, Raftery D, de Boer IH.

JCI Insight. 2018 Aug 23;3(16). pii: 122219. doi: 10.1172/jci.insight.122219. [Epub ahead of print]

11.

Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level.

Hwang YC, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ.

Diabetes Metab J. 2018 Apr 25. [Epub ahead of print]

PMID:
30112879
12.

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice.

Templin AT, Meier DT, Willard JR, Wolden-Hanson T, Conway K, Lin YG, Gillespie PJ, Bokvist KB, Attardo G, Kahn SE, Scheuner D, Hull RL.

Diabetologia. 2018 Oct;61(10):2215-2224. doi: 10.1007/s00125-018-4695-y. Epub 2018 Jul 25.

PMID:
30046852
13.

Novel approaches to restore beta cell function in prediabetes and type 2 diabetes.

Salunkhe VA, Veluthakal R, Kahn SE, Thurmond DC.

Diabetologia. 2018 Sep;61(9):1895-1901. doi: 10.1007/s00125-018-4658-3. Epub 2018 Jun 8. Review.

PMID:
29947922
14.

Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology.

Riddle MC, Bakris G, Boulton AJM, Blonde L, D'Alessio D, Greene EL, de Groot M, Hood K, Hu FB, Kahn SE, Kaul S, LeRoith D, Moses RG, Rich SS, Rosenstock J, Tamborlane WV, Wylie-Rosett J, Reynolds L.

Diabetes Care. 2018 Jul;41(7):1327-1329. doi: 10.2337/dci18-0035. No abstract available.

PMID:
29934474
15.

Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level.

Hwang YC, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ.

Diabetes Metab J. 2018 Jun;42(3):198-206. doi: 10.4093/dmj.2017.0100. Epub 2018 Apr 25.

16.

Natural history of impaired glucose tolerance in Japanese Americans: Change in visceral adiposity is associated with remission from impaired glucose tolerance to normal glucose tolerance.

Onishi Y, Hayashi T, Sato KK, Leonetti DL, Kahn SE, Fujimoto WY, Boyko EJ.

Diabetes Res Clin Pract. 2018 Aug;142:303-311. doi: 10.1016/j.diabres.2018.05.045. Epub 2018 May 30.

PMID:
29859271
17.

An Exercise Intervention to Unravel the Mechanisms Underlying Insulin Resistance in a Cohort of Black South African Women: Protocol for a Randomized Controlled Trial and Baseline Characteristics of Participants.

Goedecke JH, Mendham AE, Clamp L, Nono Nankam PA, Fortuin-de Smidt MC, Phiri L, Micklesfield LK, Keswell D, Woudberg NJ, Lecour S, Alhamud A, Kaba M, Lutomia FM, van Jaarsveld PJ, de Villiers A, Kahn SE, Chorell E, Hauksson J, Olsson T.

JMIR Res Protoc. 2018 Apr 18;7(4):e75. doi: 10.2196/resprot.9098.

18.

Erratum. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care 2017;40:1668-1677.

Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, Lorenzo C, Pi-Sunyer X, Venditti E, Ye W; Diabetes Prevention Program Research Group.

Diabetes Care. 2018 Apr;41(4):913. doi: 10.2337/dc18-er04. Epub 2018 Feb 23. No abstract available.

19.

Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health Study.

Mukamal KJ, Siscovick DS, de Boer IH, Ix JH, Kizer JR, Djoussé L, Fitzpatrick AL, Tracy RP, Boyko EJ, Kahn SE, Arnold AM.

J Am Geriatr Soc. 2018 Feb;66(2):289-296. doi: 10.1111/jgs.15205.

PMID:
29431855
20.

Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study.

Houston DK, Neiberg RH, Miller ME, Hill JO, Jakicic JM, Johnson KC, Gregg EW, Hubbard VS, Pi-Sunyer X, Rejeski WJ, Wing RR, Bantle JP, Beale E, Berkowitz RI, Cassidy-Begay M, Clark JM, Coday M, Delahanty LM, Dutton G, Egan C, Foreyt JP, Greenway FL, Hazuda HP, Hergenroeder A, Horton ES, Jeffery RW, Kahn SE, Kure A, Knowler WC, Lewis CE, Martin CK, Michaels S, Montez MG, Nathan DM, Patricio J, Peters A, Pownall H, Regensteiner J, Steinburg H, Wadden TA, White K, Yanovski SZ, Zhang P, Kritchevsky SB.

J Gerontol A Biol Sci Med Sci. 2018 Oct 8;73(11):1552-1559. doi: 10.1093/gerona/glx204.

PMID:
29053861
21.

Effects of combination of change in visceral fat and thigh muscle mass on the development of type 2 diabetes.

Han SJ, Kim SK, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ.

Diabetes Res Clin Pract. 2017 Dec;134:131-138. doi: 10.1016/j.diabres.2017.10.003. Epub 2017 Oct 12.

22.

Low Plasma Adiponectin Concentrations Predict Increases in Visceral Adiposity and Insulin Resistance.

Han SJ, Boyko EJ, Fujimoto WY, Kahn SE, Leonetti DL.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4626-4633. doi: 10.1210/jc.2017-01703.

23.

Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.

Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, Lorenzo C, Pi-Sunyer X, Venditti E, Ye W; Diabetes Prevention Program Research Group.

Diabetes Care. 2017 Dec;40(12):1668-1677. doi: 10.2337/dc17-1116. Epub 2017 Oct 11. Erratum in: Diabetes Care. 2018 Feb 23;:.

24.

Change in visceral adiposity is an independent predictor of future arterial pulse pressure.

Han SJ, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ.

J Hypertens. 2018 Feb;36(2):299-305. doi: 10.1097/HJH.0000000000001532.

PMID:
28857792
25.

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS).

Perreault L, Pan Q, Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Mather KJ, Knowler WC; Diabetes Prevention Program Research Group.

Diabet Med. 2017 Dec;34(12):1747-1755. doi: 10.1111/dme.13453. Epub 2017 Sep 19.

26.

Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.

Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM; Diabetes Prevention Program Research Group.

Diabetologia. 2017 Sep;60(9):1601-1611. doi: 10.1007/s00125-017-4361-9. Epub 2017 Aug 2. Review.

27.

Apoptosis Repressor With Caspase Recruitment Domain Ameliorates Amyloid-Induced β-Cell Apoptosis and JNK Pathway Activation.

Templin AT, Samarasekera T, Meier DT, Hogan MF, Mellati M, Crow MT, Kitsis RN, Zraika S, Hull RL, Kahn SE.

Diabetes. 2017 Oct;66(10):2636-2645. doi: 10.2337/db16-1352. Epub 2017 Jul 20.

28.

The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial.

Johnson KC, Bray GA, Cheskin LJ, Clark JM, Egan CM, Foreyt JP, Garcia KR, Glasser S, Greenway FL, Gregg EW, Hazuda HP, Hergenroeder A, Hill JO, Horton ES, Jakicic JM, Jeffery RW, Kahn SE, Knowler WC, Lewis CE, Miller M, Montez MG, Nathan DM, Patricio JL, Peters AL, Pi-Sunyer X, Pownall HJ, Reboussin D, Redmon JB, Steinberg H, Wadden TA, Wagenknecht LE, Wing RR, Womack CR, Yanovski SZ, Zhang P, Schwartz AV; Look AHEAD Study Group.

J Bone Miner Res. 2017 Nov;32(11):2278-2287. doi: 10.1002/jbmr.3214. Epub 2017 Jul 28.

29.

Review of methods for measuring β-cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium.

Hannon TS, Kahn SE, Utzschneider KM, Buchanan TA, Nadeau KJ, Zeitler PS, Ehrmann DA, Arslanian SA, Caprio S, Edelstein SL, Savage PJ, Mather KJ; RISE Consortium.

Diabetes Obes Metab. 2018 Jan;20(1):14-24. doi: 10.1111/dom.13005. Epub 2017 Jun 22. Review.

30.

Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention.

Billings LK, Jablonski KA, Warner AS, Cheng YC, McAteer JB, Tipton L, Shuldiner AR, Ehrmann DA, Manning AK, Dabelea D, Franks PW, Kahn SE, Pollin TI, Knowler WC, Altshuler D, Florez JC; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2678-2689. doi: 10.1210/jc.2016-3429.

31.

Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.

Espeland MA, Luchsinger JA, Baker LD, Neiberg R, Kahn SE, Arnold SE, Wing RR, Blackburn GL, Bray G, Evans M, Hazuda HP, Jeffery RW, Wilson VM, Clark JM, Coday M, Demos-McDermott K, Foreyt JP, Greenway F, Hill JO, Horton ES, Jakicic JM, Johnson KC, Knowler WC, Lewis CE, Nathan DM, Peters A, Pi-Sunyer X, Pownall H, Wadden TA, Rapp SR; Look AHEAD Study Group.

Neurology. 2017 May 23;88(21):2026-2035. doi: 10.1212/WNL.0000000000003955. Epub 2017 Apr 26.

32.

Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance.

Marathe CS, Rayner CK, Lange K, Bound M, Wishart J, Jones KL, Kahn SE, Horowitz M.

Physiol Rep. 2017 Feb;5(4). pii: e13122. doi: 10.14814/phy2.13122. Epub 2017 Feb 27.

33.

Greater visceral abdominal fat is associated with a lower probability of conversion of prehypertension to normotension.

Hwang YC, Fujimoto WY, Kahn SE, Leonetti DL, Boyko EJ.

J Hypertens. 2017 Jun;35(6):1213-1218. doi: 10.1097/HJH.0000000000001296.

PMID:
28169882
34.

Evidence That the Sympathetic Nervous System Elicits Rapid, Coordinated, and Reciprocal Adjustments of Insulin Secretion and Insulin Sensitivity During Cold Exposure.

Morton GJ, Muta K, Kaiyala KJ, Rojas JM, Scarlett JM, Matsen ME, Nelson JT, Acharya NK, Piccinini F, Stefanovski D, Bergman RN, Taborsky GJ Jr, Kahn SE, Schwartz MW.

Diabetes. 2017 Apr;66(4):823-834. doi: 10.2337/db16-1351. Epub 2017 Jan 23.

35.

Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201.

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE.

Diabetes Care. 2017 Feb;40(2):e23-e24. doi: 10.2337/dci16-0036. No abstract available.

36.

Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp.

Ahmad I, Zelnick LR, Robinson NR, Hung AM, Kestenbaum B, Utzschneider KM, Kahn SE, de Boer IH.

Am J Physiol Endocrinol Metab. 2017 Mar 1;312(3):E175-E182. doi: 10.1152/ajpendo.00394.2016. Epub 2017 Jan 10.

37.

Diabetes Care: "Taking It to the Limit One More Time".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Kahn SE, Weinger K, Blonde L, de Groot M, Rich S, D'Alessio D, Reynolds L, Riddle MC.

Diabetes Care. 2017 Jan;40(1):3-6. doi: 10.2337/dc16-2326. No abstract available.

38.

Physical activity and metabolic health in chronic kidney disease: a cross-sectional study.

Bowlby W, Zelnick LR, Henry C, Himmelfarb J, Kahn SE, Kestenbaum B, Robinson-Cohen C, Utzschneider KM, de Boer IH.

BMC Nephrol. 2016 Nov 22;17(1):187.

39.

Defining the Path Forward: Guidance for Laboratory Medicine Guidelines.

Kahn SE, Jones PM, Chin AC, Christenson RH.

EJIFCC. 2015 Aug 24;26(3):158-67. eCollection 2015 Aug.

40.

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Buse JB, Tuomilehto J, Fleming GA, Ferrannini E, Gerstein HC, Bennett PH, Ramachandran A, Raz I, Rosenstock J, Kahn SE.

Diabetes Care. 2016 Jul;39(7):1186-201. doi: 10.2337/dc16-0873. Epub 2016 Jun 9. Review.

41.

SGLT2 Inhibitors-Sweet Success for Diabetic Kidney Disease?

de Boer IH, Kahn SE.

J Am Soc Nephrol. 2017 Jan;28(1):7-10. doi: 10.1681/ASN.2016060650. Epub 2016 Aug 18. No abstract available.

42.

Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro.

Hogan MF, Meier DT, Zraika S, Templin AT, Mellati M, Hull RL, Leissring MA, Kahn SE.

Endocrinology. 2016 Sep;157(9):3462-8. doi: 10.1210/en.2016-1410. Epub 2016 Jul 12.

43.

The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets.

Meier DT, Entrup L, Templin AT, Hogan MF, Mellati M, Zraika S, Hull RL, Kahn SE.

Diabetologia. 2016 Oct;59(10):2166-71. doi: 10.1007/s00125-016-4045-x. Epub 2016 Sep 1.

44.

Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD.

de Boer IH, Zelnick L, Afkarian M, Ayers E, Curtin L, Himmelfarb J, Ikizler TA, Kahn SE, Kestenbaum B, Utzschneider K.

J Am Soc Nephrol. 2016 Sep;27(9):2861-71. doi: 10.1681/ASN.2015070756. Epub 2016 Jan 28.

45.

Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia.

Hwang YC, Fujimoto WY, Hayashi T, Kahn SE, Leonetti DL, Boyko EJ.

J Clin Endocrinol Metab. 2016 Feb;101(2):678-85. doi: 10.1210/jc.2015-3246. Epub 2015 Dec 4.

46.

Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD.

Belalcazar LM, Papandonatos GD, Erar B, Peter I, Alkofide H, Balasubramanyam A, Brautbar A, Kahn SE, Knowler WC, Ballantyne CM, McCaffery JM, Huggins GS; Genetics Subgroup of the Look AHEAD Study*.

Circ Cardiovasc Genet. 2016 Feb;9(1):71-8. doi: 10.1161/CIRCGENETICS.115.001192. Epub 2015 Nov 17.

47.

Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants.

Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetes. 2016 Feb;65(2):520-6. doi: 10.2337/db15-0950. Epub 2015 Nov 2.

48.

Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity.

Meier DT, Tu LH, Zraika S, Hogan MF, Templin AT, Hull RL, Raleigh DP, Kahn SE.

J Biol Chem. 2015 Dec 18;290(51):30475-85. doi: 10.1074/jbc.M115.676692. Epub 2015 Oct 19.

49.

Response to Comments on Nolan et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes 2015;64:673-686.

Nolan CJ, Ruderman NB, Kahn SE, Pedersen O, Prentki M.

Diabetes. 2015 Oct;64(10):e38-9. doi: 10.2337/dbi15-0002. No abstract available.

50.

Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans.

Hwang YC, Hayashi T, Fujimoto WY, Kahn SE, Leonetti DL, McNeely MJ, Boyko EJ.

Diabetes Care. 2015 Nov;38(11):2100-5. doi: 10.2337/dc15-0625. Epub 2015 Sep 17.

Supplemental Content

Support Center